Dana Blankenhorn

Dana Blankenhorn

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

Twilio’s Post-Pandemic Story Looks Good

Twilio is not broken, but the stock was. The company is moving ahead with smart acquisitions and growth is coming back into fashion.

Is It Finally Time to Start Valuing Walmart Stock Like Amazon?

Walmart is finally going toe to toe with Amazon's retail operations, meaning it may be time to value WMT stock a bit differently.

Both Tyson Foods Stock and Chicken Wings Hit High Prices. Only One’s a Buy

During the 2010s consolidation let TSN stock outperform the average stock. The pandemic interrupted that, but its end has improved the outlook for low-cost producer Tyson Foods.

Investing in the Future of General Motor’s EV Is Not Ideal

Investors are losing patience with General Motor's CEO Mary Barra's plans to turn the company into an electric vehicle powerhouse.

Nvidia: After the Arm Failure

The chip shortage will ease and Nvidia will be opening up new application spaces for what were once just graphics chips.

Why Upcoming Earnings Are Important for Upstart Stock

Upstart reports earnings soon, and the recent downdraft is looking increasingly like a buying opportunity for UPST stock.

Does Cassava Sciences and Its Alzheimer’s Drug Really Have What It Takes?

Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows. SAVA stock is pure speculation either way.

Palantir Stock Embodies the Perils of Buying Growth

PLTR stock is still growing, but I question how far Palantir can really go with a completely proprietary and opaque business model.

Is Beyond Meat Stock Beyond Help?

Beyond Meat continues to attract big partnerships and positive analyst coverage despite the poor performance of BYND stock.

Chinese EV Nio Is Everything Lucid Could Be

A 2020 government aid deal gave Nio the capital and production capacity to compete in China's crowded electric car market.